• Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

    Read more
  • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics Named the Stock Exchange Company of the Year

    Read more
  • Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

    Read more
  • Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million

    Read more
  • Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

    Read more
  • Ryvu Therapeutics initiates public offering of shares

    Read more
  • BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates

    Read more
  • Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

    Read more
  • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

    Read more
  • Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

    Read more
  • Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission

    Read more
  • EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million

    Read more
  • Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

    Read more
  • Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

    Read more
  • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

    Read more
  • Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

    Read more
  • Ryvu Therapeutics to Participate in Upcoming Investor Conferences

    Read more
  • Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).

    Read more
  • Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    Read more
  • Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

    Read more
  • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

    Read more
  • Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

    Read more
  • Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

    Read more
  • Ryvu announces option to license inflammation program exercised by Galapagos NV

    Read more
  • Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

    Read more
  • Ryvu Therapeutics Reports Q3 2021 Financial Results

    Read more
  • Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

    Read more
  • Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

    Read more
  • Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

    Read more
  • Ryvu Therapeutics Reports 2021 Half-Year Financial Results

    Read more
  • Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

    Read more
  • Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

    Read more
  • Ryvu Therapeutics to participate in upcoming global investor conferences

    Read more
  • FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Read more
  • Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

    Read more
  • Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

    Read more
  • Ryvu Therapeutics among the founding members of 30% Club Poland

    Read more
  • Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

    Read more
  • Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

    Read more
  • SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

    Read more
  • Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

    Read more
  • Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

    Read more
  • Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

    Read more
  • Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

    Read more
  • Ryvu Therapeutics Reports First Quarter 2021 Financial Results

    Read more
  • Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

    Read more
  • Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Read more
  • Ryvu Therapeutics at BIO-Europe Spring

    Read more
  • Ryvu Therapeutics reports financial results for 2020

    Read more
  • Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition

    Read more
  • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting

    Read more
  • Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

    Read more
  • Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

    Read more
  • Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors

    Read more
  • "Dream with Ryvu" - a corporate movie by Ryvu Therapeutics

    Read more
  • Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry

    Read more
  • Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

    Read more
  • Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski

    Read more
  • Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board

    Read more
  • Ryvu Therapeutics Reports Q3 2020 Financial Results

    Read more
  • Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference

    Read more
  • Ryvu Therapeutics at BIO-Europe 2020

    Read more
  • Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)

    Read more
  • First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

    Read more
  • Ryvu Therapeutics Reports 2020 Half-Year Financial Results

    Read more
  • Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

    Read more
  • Ryvu Therapeutics raised over USD 36 million from its share issue

    Read more
  • The share issue price in Ryvu Therapeutics public offering set at PLN 60

    Read more
  • Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.

    Read more
  • Ryvu Therapeutics Reports First Quarter 2020 Financial Results

    Read more
  • Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

    Read more
  • NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

    Read more
  • Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

    Read more
  • Ryvu Therapeutics at BIO Digital 2020

    Read more
  • Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

    Read more
  • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II

    Read more
  • Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress

    Read more
  • Galapagos and Ryvu announce research collaboration

    Read more
  • Ryvu Therapeutics Reports Annual 2019 Financial Results

    Read more
  • Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference

    Read more
  • Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia

    Read more
  • Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

    Read more
  • Ryvu Therapeutics at BIO-Europe Spring 2020

    Read more
  • Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference

    Read more
  • Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept

    Read more
  • Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors

    Read more
  • Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules

    Read more
  • Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

    Read more
  • Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

    Read more
  • Ryvu Therapeutics to Present at BIO-Europe 2019

    Read more
  • Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

    Read more
  • Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    Read more
  • Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

    Read more
  • Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

    Read more
  • Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

    Read more
  • Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

    Read more
  • Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

    Read more
  • Selvita to Present at Upcoming Conferences in September

    Read more
  • Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

    Read more
  • Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

    Read more
  • Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

    Read more
  • Selvita to present at the 2019 HCW Global Life Sciences Conference in London

    Read more
  • Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

    Read more
  • Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Read more
  • Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

    Read more
  • Selvita to Present at Biotech Showcase 2019 in San Francisco

    Read more
  • Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

    Read more
  • Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

    Read more
  • Selvita to present new data from its oncology programs at the upcoming SITC 2018

    Read more
  • Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

    Read more
  • Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

    Read more
  • Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

    Read more
  • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

    Read more
  • Selvita publishes research results on SEL24 in Oncotarget

    Read more
  • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

    Read more
  • Selvita Announces Successful Completion of $41 M Book Building

    Read more
  • FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

    Read more
  • Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

    Read more
  • Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Read more
  • Selvita and Menarini present together at the European Business Development Conference

    Read more
  • Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

    Read more
  • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

    Read more
  • Selvita presents at 18th Drug Discovery Summit in Berlin

    Read more
  • Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

    Read more
  • Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

    Read more
  • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Read more
  • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

    Read more
  • Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

    Read more
  • Selvita to present at Biotech Showcase 2017 in San Francisco

    Read more
  • Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

    Read more
  • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

    Read more
  • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

    Read more
  • Epidarex Capital Creates Nodthera Limite

    Read more
  • Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

    Read more
  • Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

    Read more
  • Selvita wins the European Rising Star Award

    Read more
  • The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

    Read more
  • Merck and Selvita Announce Drug Discovery Collaboration

    Read more
  • Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

    Read more
  • H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

    Read more
  • Selvita receives the Economic Award of the President of Poland

    Read more
  • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

    Read more
  • Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

    Read more
  • Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

    Read more
  • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

    Read more
    • Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

      Read more
    • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics Named the Stock Exchange Company of the Year

      Read more
    • Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

      Read more
    • Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million

      Read more
    • Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

      Read more
    • Ryvu Therapeutics initiates public offering of shares

      Read more
    • BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates

      Read more
    • Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

      Read more
    • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

      Read more
    • Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

      Read more
    • Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission

      Read more
    • EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million

      Read more
    • Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

      Read more
    • Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

      Read more
    • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

      Read more
    • Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

      Read more
    • Ryvu Therapeutics to Participate in Upcoming Investor Conferences

      Read more
    • Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).

      Read more
    • Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      Read more
    • Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

      Read more
    • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

      Read more
    • Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

      Read more
    • Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

      Read more
    • Ryvu announces option to license inflammation program exercised by Galapagos NV

      Read more
    • Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

      Read more
    • Ryvu Therapeutics Reports Q3 2021 Financial Results

      Read more
    • Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

      Read more
    • Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

      Read more
    • Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

      Read more
    • Ryvu Therapeutics Reports 2021 Half-Year Financial Results

      Read more
    • Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

      Read more
    • Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

      Read more
    • Ryvu Therapeutics to participate in upcoming global investor conferences

      Read more
    • FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Read more
    • Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

      Read more
    • Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

      Read more
    • Ryvu Therapeutics among the founding members of 30% Club Poland

      Read more
    • Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

      Read more
    • Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

      Read more
    • SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

      Read more
    • Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

      Read more
    • Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

      Read more
    • Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

      Read more
    • Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

      Read more
    • Ryvu Therapeutics Reports First Quarter 2021 Financial Results

      Read more
    • Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

      Read more
    • Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Read more
    • Ryvu Therapeutics at BIO-Europe Spring

      Read more
    • Ryvu Therapeutics reports financial results for 2020

      Read more
    • Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition

      Read more
    • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting

      Read more
    • Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

      Read more
    • Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

      Read more
    • Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors

      Read more
    • "Dream with Ryvu" - a corporate movie by Ryvu Therapeutics

      Read more
    • Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry

      Read more
    • Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

      Read more
    • Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski

      Read more
    • Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board

      Read more
    • Ryvu Therapeutics Reports Q3 2020 Financial Results

      Read more
    • Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference

      Read more
    • Ryvu Therapeutics at BIO-Europe 2020

      Read more
    • Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)

      Read more
    • First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

      Read more
    • Ryvu Therapeutics Reports 2020 Half-Year Financial Results

      Read more
    • Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

      Read more
    • Ryvu Therapeutics raised over USD 36 million from its share issue

      Read more
    • The share issue price in Ryvu Therapeutics public offering set at PLN 60

      Read more
    • Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.

      Read more
    • Ryvu Therapeutics Reports First Quarter 2020 Financial Results

      Read more
    • Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

      Read more
    • NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

      Read more
    • Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

      Read more
    • Ryvu Therapeutics at BIO Digital 2020

      Read more
    • Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

      Read more
    • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II

      Read more
    • Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress

      Read more
    • Galapagos and Ryvu announce research collaboration

      Read more
    • Ryvu Therapeutics Reports Annual 2019 Financial Results

      Read more
    • Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference

      Read more
    • Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia

      Read more
    • Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

      Read more
    • Ryvu Therapeutics at BIO-Europe Spring 2020

      Read more
    • Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference

      Read more
    • Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept

      Read more
    • Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors

      Read more
    • Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules

      Read more
    • Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

      Read more
    • Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

      Read more
    • Ryvu Therapeutics to Present at BIO-Europe 2019

      Read more
    • Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

      Read more
    • Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

      Read more
    • Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

      Read more
    • Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

      Read more
    • Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

      Read more
    • Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

      Read more
    • Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

      Read more
    • Selvita to Present at Upcoming Conferences in September

      Read more
    • Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

      Read more
    • Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

      Read more
    • Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

      Read more
    • Selvita to present at the 2019 HCW Global Life Sciences Conference in London

      Read more
    • Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

      Read more
    • Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

      Read more
    • Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

      Read more
    • Selvita to Present at Biotech Showcase 2019 in San Francisco

      Read more
    • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

      Read more
    • Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

      Read more
    • Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

      Read more
    • Selvita to present new data from its oncology programs at the upcoming SITC 2018

      Read more
    • Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

      Read more
    • Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

      Read more
    • Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

      Read more
    • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

      Read more
    • Selvita publishes research results on SEL24 in Oncotarget

      Read more
    • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

      Read more
    • Selvita Announces Successful Completion of $41 M Book Building

      Read more
    • FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

      Read more
    • Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

      Read more
    • Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

      Read more
    • Selvita and Menarini present together at the European Business Development Conference

      Read more
    • Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

      Read more
    • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

      Read more
    • Selvita presents at 18th Drug Discovery Summit in Berlin

      Read more
    • Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

      Read more
    • Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

      Read more
    • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

      Read more
    • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

      Read more
    • Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

      Read more
    • Selvita to present at Biotech Showcase 2017 in San Francisco

      Read more
    • Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

      Read more
    • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

      Read more
    • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

      Read more
    • Epidarex Capital Creates Nodthera Limite

      Read more
    • Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

      Read more
    • Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

      Read more
    • Selvita wins the European Rising Star Award

      Read more
    • The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

      Read more
    • Merck and Selvita Announce Drug Discovery Collaboration

      Read more
    • Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

      Read more
    • H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

      Read more
    • Selvita receives the Economic Award of the President of Poland

      Read more
    • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

      Read more
    • Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

      Read more
    • Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

      Read more
    • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

      Read more